Extensively Hydrolyzed Formula and Infant Colic Symptoms: Secondary Analysis of a Prospective Cohort Study-Reference-Cited by-同舟云学术

Extensively Hydrolyzed Formula and Infant Colic Symptoms: Secondary Analysis of a Prospective Cohort Study

Published:2024-03-10 Issue: Volume: Page:
ISSN:0009-9228
Container-title:Clinical Pediatrics
language:en
Short-container-title:Clin Pediatr (Phila)

Author:

Brown Jerry Mack¹^ORCID,Baran Jessica Victoria¹^ORCID,Lamos Luke¹,Beacker Jesse¹,Florio Jared¹,Oliveros Lea Victoria²,Fabbrini Abigail Lea³^ORCID,Farrar Andrew Arthur³^ORCID,Vanderhoof Jon Arvid⁴,Wilsey Michael John⁵

Affiliation:

1. Office of Medical Education, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, USA

2. Office of Medical Education, Alabama College of Osteopathic Medicine, Dothan, AL, USA

3. Office of Medical Education, College of Osteopathic Medicine, Kansas City University, Kansas City, MO, USA

4. Department of Gastroenterology Hepatology and Nutrition, Boys Town Hospital, Boys Town, NE, USA

5. Department of Pediatrics, Morsani College of Medicine, University of South Florida, Tampa, FL, USA

Abstract

Cow’s milk protein allergy (CMPA) affects 2% to 3% of infants and is managed with hypoallergenic formulas. The 2022 recalls of infant formulas due to factors including contamination led to specialty formula shortages, highlighting CMPA management challenges. Understanding health care providers’ (HCPs) decision-making in transitioning to alternative formulas during shortages is crucial. Limited attention has been given to how pediatric physicians make these choices. This study utilized US HCPs’ de-identified survey data to assess driving factors when switching extensively hydrolyzed formulas during shortages. A total of 104 eligible HCPs participated, including general pediatrics, pediatric allergy/immunology, and pediatric gastroenterology specialists. Safety, tolerability, and efficacy were identified as top factors for switching formulas. Formula 1 was considered well-tolerated, patient-accepted, and safe by all HCPs. Most expressed strong belief in Formula 1’s safety and effectiveness. Findings inform CMPA management during shortages, offering guidance to HCPs for suitable formula selection and enhanced infant care.

Funder

Reckitt Benckiser Pharmaceuticals

Publisher

SAGE Publications

Link

http://journals.sagepub.com/doi/pdf/10.1177/00099228241236033

Reference24 articles.